{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:55:59Z","timestamp":1697219759271},"reference-count":8,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[1999,9,1]],"date-time":"1999-09-01T00:00:00Z","timestamp":936144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,9]]},"abstract":"ABSTRACT<\/jats:title>\n \n Gemifloxacin mesylate (SB 265805), a new fluoronaphthyridone, was tested against 359 recent clinical anaerobic isolates by the National Committee for Clinical Laboratory Standards reference agar dilution method with supplemented brucella blood agar and an inoculum of 10\n 5<\/jats:sup>\n CFU\/spot. Comparative antimicrobials tested included trovafloxacin, levofloxacin, grepafloxacin, sparfloxacin, sitafloxacin (DU-6859a), penicillin G, amoxicillin clavulanate, imipenem, cefoxitin, clindamycin, and metronidazole. The MIC\n 50<\/jats:sub>\n and MIC\n 90<\/jats:sub>\n (MICs at which 50 and 90% of the isolates were inhibited) of gemifloxacin against various organisms (with the number of strains tested in parentheses) were as follows (in micrograms per milliliter): for\n Bacteroides fragilis<\/jats:italic>\n (28), 0.5 and 2; for\n Bacteroides thetaiotaomicron<\/jats:italic>\n (24), 1 and 16; for\n Bacteroides caccae<\/jats:italic>\n (12), 1 and 16; for\n Bacteroides distasonis<\/jats:italic>\n (12), 8 and >16; for\n Bacteroides ovatus<\/jats:italic>\n (12), 4 and >16; for\n Bacteroides stercoris<\/jats:italic>\n (12), 0.5 and 0.5; for\n Bacteroides uniformis<\/jats:italic>\n (12), 1 and 4; for\n Bacteroides vulgatus<\/jats:italic>\n (11), 4 and 4; for\n Clostridium clostridioforme<\/jats:italic>\n (15), 0.5 and 0.5; for\n Clostridium difficile<\/jats:italic>\n (15), 1 and >16; for\n Clostridium innocuum<\/jats:italic>\n (13), 0.125 and 2; for\n Clostridium perfringens<\/jats:italic>\n (13), 0.06 and 0.06; for\n Clostridium ramosum<\/jats:italic>\n (14), 0.25 and 8; for\n Fusobacterium nucleatum<\/jats:italic>\n (12), 0.125 and 0.25; for\n Fusobacterium necrophorum<\/jats:italic>\n (11), 0.25 and 0.5; for\n Fusobacterium varium<\/jats:italic>\n (13), 0.5 and 1; for\n Fusobacterium<\/jats:italic>\n spp. (12), 1 and 2; for\n Peptostreptococcus anaerobius<\/jats:italic>\n (13), 0.06 and 0.06; for\n Peptostreptococcus asaccharolyticus<\/jats:italic>\n (13), 0.125 and 0.125; for\n Peptostreptococcus magnus<\/jats:italic>\n (14), 0.03 and 0.03; for\n Peptostreptococcus micros<\/jats:italic>\n (12), 0.06 and 0.06; for\n Peptostreptococcus prevotii<\/jats:italic>\n (14), 0.06 and 0.25; for\n Porphyromonas asaccharolytica<\/jats:italic>\n (11), 0.125 and 0.125; for\n Prevotella bivia<\/jats:italic>\n (10), 8 and 16; for\n Prevotella buccae<\/jats:italic>\n (10), 2 and 2; for\n Prevotella intermedia<\/jats:italic>\n (10), 0.5 and 0.5; and for\n Prevotella melaninogenica<\/jats:italic>\n (11), 1 and 1. Gemifloxacin mesylate (SB 265805) was 1 to 4 dilutions more active than trovafloxacin against fusobacteria and peptostreptococci, and the two drugs were equivalent against clostridia and\n P. asaccharolytica<\/jats:italic>\n . Gemifloxacin was equivalent to sitafloxacin (DU 6859a) against peptostreptococci,\n C. perfringens<\/jats:italic>\n , and\n C. ramosum<\/jats:italic>\n , and sitafloxacin was 2 to 3 dilutions more active against fusobacteria. Sparfloxacin, grepafloxacin, and levofloxacin were generally less active than gemifloxacin against all anaerobes.\n <\/jats:p>","DOI":"10.1128\/aac.43.9.2231","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:35:31Z","timestamp":1539045331000},"page":"2231-2235","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":36,"title":["In Vitro Activity of Gemifloxacin (SB 265805) against Anaerobes"],"prefix":"10.1128","volume":"43","author":[{"given":"Ellie J. C.","family":"Goldstein","sequence":"first","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica\u2014University of California at Los Angeles Medical Center, Santa Monica, California 90404, and the University of California at Los Angeles School of Medicine, Los Angeles, California 90073"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane M.","family":"Citron","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica\u2014University of California at Los Angeles Medical Center, Santa Monica, California 90404, and the University of California at Los Angeles School of Medicine, Los Angeles, California 90073"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Warren","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica\u2014University of California at Los Angeles Medical Center, Santa Monica, California 90404, and the University of California at Los Angeles School of Medicine, Los Angeles, California 90073"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerin","family":"Tyrrell","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica\u2014University of California at Los Angeles Medical Center, Santa Monica, California 90404, and the University of California at Los Angeles School of Medicine, Los Angeles, California 90073"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Vreni","family":"Merriam","sequence":"additional","affiliation":[{"name":"R. M. Alden Research Laboratory, Santa Monica\u2014University of California at Los Angeles Medical Center, Santa Monica, California 90404, and the University of California at Los Angeles School of Medicine, Los Angeles, California 90073"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1128\/AAC.41.1.204","article-title":"Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.","volume":"41","author":"Cormicon M. G.","year":"1997","unstructured":"Cormicon M. G. Jones R. N. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrob. Agents Chemother. 41 1997 204 211","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_3_2","unstructured":"Holdeman\n L. V.\n Moore\n W. E. C.\n Anaerobic laboratory manual\n 4th ed.\n 1977\n Virginia Polytechnic Institute and State University\n Blacksburg"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1469-0691.1998.tb00057.x","article-title":"International multicenter investigation of LB20304, a new fluoronaphthyridone.","volume":"4","author":"Holh A. F.","year":"1998","unstructured":"Holh A. F. Frei R. Punter V. von Gravenitz A. Knapp C. Washington J. Johnson D. Jones R. N. International multicenter investigation of LB20304, a new fluoronaphthyridone. Clin. Microbiol. Infect. 4 1998 280 284","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.4.605"},{"key":"e_1_3_2_6_2","unstructured":"National Committee for Clinical Laboratory Standards\n Methods for antimicrobial susceptibility testing of anaerobic bacteria\n 4th ed.\n 1997 Approved standard. NCCLS publication no. M11-A4. National Committee for Clinical Laboratory Standards Villanova Pa."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1564"},{"key":"e_1_3_2_8_2","unstructured":"SmithKline Beecham Pharmaceuticals\n SB-265805\n Investigators brochure\n 3rd ed.\n 1998\n 20\n 24\n SmithKline Beecham Pharmaceuticals\n Philadelphia Pa"},{"key":"e_1_3_2_9_2","unstructured":"Summanen\n P.\n Baron\n E. J.\n Citron\n D. M.\n Strong\n C. A.\n Wexler\n H. M.\n Finegold\n S. M.\n Wadsworth anaerobic bacteriology manual\n 5th ed.\n 1993\n Star Publishing Co.\n Belmont Calif"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.9.2231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.9.2231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:35:10Z","timestamp":1645461310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.9.2231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["10.1128\/AAC.43.9.2231"],"URL":"https:\/\/doi.org\/10.1128\/aac.43.9.2231","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9]]},"assertion":[{"value":"1999-04-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}